<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154189</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-G000-230</org_study_id>
    <secondary_id>2019-003696-19</secondary_id>
    <nct_id>NCT04154189</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma</brief_title>
  <official_title>A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed or Refractory Osteosarcoma (OLIE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Is a Multicenter, Randomized, Open-Label, Parallel-Group, Phase 2 Study to Compare the&#xD;
      Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide Versus&#xD;
      Ifosfamide and Etoposide in Children, Adolescents, and Young Adults with Relapsed or&#xD;
      Refractory Osteosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From the date of randomization to the date of the first documentation of PD or death, whichever occurs first (up to approximately 36 months)</time_frame>
    <description>PFS by independent imaging review (IIR) is defined as the time from the date of randomization to the date of the first documentation of PD or death (whichever occurs first) as determined by IIR using RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Rate at Month 4 (PFS-4m Rate)</measure>
    <time_frame>Month 4</time_frame>
    <description>PFS-4m rate by IIR is defined as the percentage of participants who will be alive and without PD at 4 months from the randomization date as determined by IIR of radiological imaging using RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Rate at 1 Year or Month 12 (PFS-1y rate)</measure>
    <time_frame>Month 12</time_frame>
    <description>Progression-free survival rate at 1 year or 12 months (PFS-1y rate) by IIR is defined as the percentage of participants who will be alive and without PD at 1 year from the randomization date as determined by IIR of radiological imaging using RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of randomization to the date of death from any cause (up to approximately 36 months)</time_frame>
    <description>OS is defined as the time from the date of randomization to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate at Month 4 (ORR-4m)</measure>
    <time_frame>Month 4</time_frame>
    <description>ORR-4m is defined as the percentage of participants who will have best overall response of complete response (CR) or partial response (PR) as determined by IIR using RECIST 1.1 within the first 4 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From the date of randomization to the date of the first documentation of CR or PR, whichever occurs first (up to approximately 36 months)</time_frame>
    <description>ORR by IIR is defined as the percentage of participants who will have best overall response of CR or PR as determined by IIR using RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From Baseline up to 30 days after the last dose of study drug or until resolution, whichever comes first (up to approximately 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Lenvatinib - Arm A</measure>
    <time_frame>Cycle 1 Day 1: 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: Predose, 0.5-4 hours and 6-10 hours postdose; Cycle 2 Day 1: Predose (Cycle length = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Score for all Pediatric Quality of Life Inventory (PedsQL) Scales Including Generic Core Scales and Cancer Modules</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Health-Related Quality of Life (HRQOL): The PedsQL is a modular instrument designed to measure HRQoL in pediatric and adults population. The PedsQL 4.0 Generic Core Scales are multidimensional child self-report and parent proxy-report scales developed as the generic core measure to be integrated with the PedsQL disease specific modules. The PedsQL 3.0 Cancer Module was designed to measure pediatric cancer specific HRQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability and Acceptability of the Suspension Formulation of Lenvatinib in Participants Receiving the Suspension Formulation, as Assessed Using Palatability Questionnaire</measure>
    <time_frame>Cycle 1 Day 1 (Cycle length = 21 days)</time_frame>
    <description>The palatability and acceptability of the suspension formulation questionnaire will assess the following parameters: taste, appearance, smell, how does it feel in the mouth and overall acceptability. Each parameter will be measured using a 7-point facial Hedonic scale grading parameters according to the following values: super bad, really bad, bad, may be good or may be bad, good, really good, or super good. For each parameter, the percentage of responses per grading value will be described.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Randomization Phase: Lenvatinib + Ifosfamide + Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomization Phase: Ifosfamide + Etoposide and Lenvatinib (Optional)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with relapsed or refractory osteosarcoma will receive ifosfamide with etoposide. Participants with relapsed or refractory osteosarcoma may receive optional lenvatinib plus or minus chemotherapy (Ifosfamide and Etoposide) if disease progression is observed in study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib 14 milligrams per square meter (mg/m^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.&#xD;
An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules.</description>
    <arm_group_label>Randomization Phase: Lenvatinib + Ifosfamide + Etoposide</arm_group_label>
    <other_name>E7080</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Ifosfamide 3000 milligrams per square meter per day (mg/m^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.</description>
    <arm_group_label>Randomization Phase: Ifosfamide + Etoposide and Lenvatinib (Optional)</arm_group_label>
    <arm_group_label>Randomization Phase: Lenvatinib + Ifosfamide + Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 100 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.</description>
    <arm_group_label>Randomization Phase: Ifosfamide + Etoposide and Lenvatinib (Optional)</arm_group_label>
    <arm_group_label>Randomization Phase: Lenvatinib + Ifosfamide + Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib 14 mg/m^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors [RECIST] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.</description>
    <arm_group_label>Randomization Phase: Ifosfamide + Etoposide and Lenvatinib (Optional)</arm_group_label>
    <other_name>E7080</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed diagnosis of high grade osteosarcoma&#xD;
&#xD;
          2. Refractory or relapsed osteosarcoma after 1 to 2 prior lines of systemic treatments&#xD;
&#xD;
          3. Measurable or evaluable disease per RECIST 1.1.&#xD;
&#xD;
          4. Life expectancy of 12 weeks or more&#xD;
&#xD;
          5. Lansky play score greater than or equal to (&gt;=) 50 Percent (%) or Karnofsky&#xD;
             Performance Status score &gt;=50%. Use Karnofsky for participants &gt;=16 years of age and&#xD;
             Lansky for participants less than (&lt;)16 years of age. Participants who are unable to&#xD;
             walk because of paralysis, but who are able to perform activities of daily living&#xD;
             while wheelchair bound, will be considered ambulatory for the purpose of assessing the&#xD;
             performance score&#xD;
&#xD;
          6. Adequate organ function per blood work&#xD;
&#xD;
          7. Adequate cardiac function as evidenced by left ventricular ejection fraction (LVEF)&#xD;
             &gt;=50% at baseline as determined by echocardiography or multigated acquisition (MUGA)&#xD;
             scan&#xD;
&#xD;
          8. Adequately controlled blood pressure (BP) with or without antihypertensive&#xD;
             medications, defined as:&#xD;
&#xD;
             BP &lt;95th percentile for sex, age, and height/length at screening (as per National&#xD;
             Heart Lung and Blood Institute guidelines) and no change in antihypertensive&#xD;
             medications within 1 week prior to Cycle 1 Day 1. Participants &gt;18 years of age should&#xD;
             have BP less than or equal to (&lt;=) 150/90 millimeters of Mercury at screening and no&#xD;
             change in antihypertensive therapy within 1 week prior to Cycle 1 Day 1&#xD;
&#xD;
          9. Washout before Cycle 1 Day 1 of 3 weeks in case of prior chemotherapy, 6 weeks if&#xD;
             treatment included nitrosoureas; 4 weeks for definitive radiotherapy, 2 weeks for&#xD;
             palliative radiotherapy; and 3 months from high-dose chemotherapy and stem cell&#xD;
             rescue. For all other anti-cancer therapies, washout before Cycle 1 Day 1 of at least&#xD;
             5 half-lives (or at least 28 days, whichever is shorter). Participants must have&#xD;
             recovered [to Grade &lt;=1, except for alopecia, ototoxicity, and Grade &lt;=2 peripheral&#xD;
             neuropathy, per common terminology criteria for adverse events (CTCAE) v5.0] from the&#xD;
             acute toxic effects of all prior anticancer therapy before Cycle 1 Day 1&#xD;
&#xD;
         10. Must have no prior history of lenvatinib treatment&#xD;
&#xD;
        Eligibility for optional lenvatinib crossover:&#xD;
&#xD;
          1. Disease progression per RECIST 1.1 (as confirmed by IIR for all participants who&#xD;
             crossover prior to the study data-cut)&#xD;
&#xD;
          2. No new systemic anti-cancer medication administered after the last dose of study drugs&#xD;
&#xD;
          3. Meets all safety parameters listed in the inclusion criteria and none listed in the&#xD;
             exclusion criteria&#xD;
&#xD;
          4. Study is ongoing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any active infection or infectious illness unless fully recovered prior to Cycle 1 Day&#xD;
             1 (that is, no longer requiring systemic treatment)&#xD;
&#xD;
          2. Participants with central nervous system metastases are not eligible, unless they have&#xD;
             completed local therapy (example, whole brain radiation therapy, surgery or&#xD;
             radiosurgery) and have discontinued the use of corticosteroids for this indication for&#xD;
             at least 2 weeks before Cycle 1 Day 1&#xD;
&#xD;
          3. Active second malignancy within 2 years prior to enrollment ([in addition to&#xD;
             osteosarcoma], but not including definitively treated superficial melanoma,&#xD;
             carcinoma-in-situ, basal or squamous cell carcinoma of the skin)&#xD;
&#xD;
          4. Has had major surgery within 3 weeks prior to Cycle 1 Day 1. Note: Adequate wound&#xD;
             healing after major surgery must be assessed clinically, independent of time elapsed&#xD;
             for eligibility&#xD;
&#xD;
          5. A clinically significant electrocardiogram (ECG) abnormality, including a marked&#xD;
             baseline prolonged QT or corrected QT (QTc) interval (example, a repeated&#xD;
             demonstration of a QTc interval greater than [&gt;] 480 millisecond [msec])&#xD;
&#xD;
          6. Has clinically significant cardiovascular disease within 6 months from first dose of&#xD;
             study intervention, including New York Heart Association Class III or IV congestive&#xD;
             heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or&#xD;
             cardiac arrhythmia associated with hemodynamic instability. Note: Medically controlled&#xD;
             arrhythmia would be permitted&#xD;
&#xD;
          7. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition&#xD;
             that in the opinion of the investigator might affect the absorption of lenvatinib&#xD;
&#xD;
          8. Pre-existing Grade &gt;=3 gastrointestinal or non-gastrointestinal fistula&#xD;
&#xD;
          9. Gastrointestinal bleeding or active hemoptysis (bright red blood of at least 1 divided&#xD;
             [/] by 2 teaspoon) within 3 weeks prior to Cycle 1 Day 1&#xD;
&#xD;
         10. Radiographic evidence of intratumoral cavitation, encasement, or invasion of a major&#xD;
             blood vessel. Additionally, the degree of proximity to major blood vessels should be&#xD;
             considered for exclusion because of the potential risk of severe hemorrhage associated&#xD;
             with tumor shrinkage/necrosis after lenvatinib therapy&#xD;
&#xD;
         11. History of ifosfamide-related Grade &gt;=3 nephrotoxicity or encephalopathy&#xD;
&#xD;
         12. Known to be human immunodeficiency virus (HIV) positive&#xD;
&#xD;
         13. Known active Hepatitis B (example, Hepatitis B surface antigen [HBsAg] reactive) or&#xD;
             Hepatitis C (example, hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is&#xD;
             detected). Note: Testing for Hepatitis B or Hepatitis C is required at screening only&#xD;
             when mandated by local health authority&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information</last_name>
    <phone>1-888-274-2378</phone>
    <email>esi_oncmedinfo@eisai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospitals</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riley Hospital For Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cook Children's Health Care System</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse Hospital</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Perth Childrens Hospital</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queensland Children's Hospital</name>
      <address>
        <city>South Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Anna Kinderspital</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital For Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopistollinen sairaala</name>
      <address>
        <city>Tampere</city>
        <state>Länsi-Suomen Lääni</state>
        <zip>FI-33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopitaux de La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Mère Et de L'enfant</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Des Enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hong Kong Children's Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Health Ireland at Crumlin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituti Ortopedici Rizzoli</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera A Meyer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Maxima Center for Pediatric Oncology</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Starship Children's Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barn Och Ungdomssjukhus</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinderspital Zürich - Eleonorenstiftung</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Children</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds Children Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Childrens Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteosarcoma</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>Ifosfamide</keyword>
  <keyword>Etoposide</keyword>
  <keyword>E7080</keyword>
  <keyword>Relapsed or Refractory Osteosarcoma</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

